300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Cryptocurrency
Film
Oil and Gas
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Medical Device
Education
Sports
Wellness
Biotechnology
Automotive
eSports
Software
Legal
Renewable Energy
Crowdfunding
Venture Capital
Social
Infrastructure
Beauty
Fashion
Recruiting
Climate
LGBT
Web3
Cannabis
Medical
Celebrity
Theatre
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Manufacturing
Art
Real Estate
Sporting Goods
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
FinTech
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Finance
Community
Media (Entertainment)
Digital Media
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Gibraltar
Singapore
Brazil
LATAM
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Kenya
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Paraguay
Botswana
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
Portugal
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Albania
Asia
Spain
Argentina
Bangladesh
Europe
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Qatar
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Angola
Cyprus
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Yusuf Hamied, Angel Investor

Yusuf Hamied

Angel Investor

Mumbai, India

Yusuf Hamied is a Cambridge-educated Chemist and the Non-Executive Chairman of the Board of Directors at Cipla, a large generic pharmaceuticals company founded in 1935 by his father, Khwaja Abdul Hamied. Yusuf became a global celebrity for his role in defying Western multinational pharmaceutical companies in order to provide generic AIDS treatmentsand other drugs to treat poor people in the developing world. After completing his doctorate in 1960, Yusuf joined the family company and vowed to break the dominance of foreign multinationals over the Indian pharmaceutical market by developing cheap generic drugs. Yusuf helped persuade the Indian government to change Indian patent law in 1972, permitting medicines to be copied even if they were under international patent, as long as the process was not the same. The law transformed the Indian pharmaceutical industry, enabling his and other companies to grow by manufacturing generic drugs. In 2001 Yusuf convulsed the global healthcare industry by promising and then delivering a triple drug cocktail, Triomune, that helped fight against HIV and AIDS at prices far lower than those available internationally. Yusuf discusses his subsequent anger when, in 2005, the Indian government brought its patent laws in line with those of the developed world, prohibiting the copying of drugs patented after 1995 without a license and his resentment that he had thereafter “to go with a begging bowl to the multinationals” for licenses. This interview provides not only a personal perspective on how India’s third largest pharmaceutical firm was created, but contributes to the broad debates on the costs and benefits of intellectual property laws, particularly their impact on people who are denied life-saving drugs by their inability to pay for them. Working for Cipla as Managing Director for nearly 52 years, Yusuf was also the 28th richest Indian during one time. ‘CNN-IBN Indian of the year’ and one among the ’25 greatest global living legends’ were the titles that Yusuf won for his reign in the pharma world majorly for making medicines affordable to the poor. Yusuf was awarded with the civil honorary Padma Bhushan from then president APJ Abdul Kalam in the year 2005 for his fight against AIDS, which he often said was going to be as damaging to the society as a massive earthquake would be, if ignored. Yusuf earned his Bachelor's degree (1956), Master's degree (1957) and Ph.D. (1960) in Chemistry from University of Cambridge.

Total investments:
1
Last investment:
Lead investor:
0%

Last updated:

Industries Yusuf Hamied invests in

MedicalMedical Device

Stages Yusuf Hamied invests in

Seed

Countries Yusuf Hamied invests in

United Kingdom

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Medical 1 (100%)
  • Medical Device 1 (100%)

Investments

CompanyDescriptionRoundLinks
1inhaler 1inhaler
1inhaler operates as a developer of drug delivery device. $2.5M / Seed / Nov 27, 2023

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Cryptocurrency
Film
Oil and Gas
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Medical Device
Education
Sports
Wellness
Biotechnology
Automotive
eSports
Software
Legal
Renewable Energy
Crowdfunding
Venture Capital
Social
Infrastructure
Beauty
Fashion
Recruiting
Climate
LGBT
Web3
Cannabis
Medical
Celebrity
Theatre
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Manufacturing
Art
Real Estate
Sporting Goods
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
FinTech
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Finance
Community
Media (Entertainment)
Digital Media
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Gibraltar
Singapore
Brazil
LATAM
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Kenya
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Paraguay
Botswana
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
Portugal
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Albania
Asia
Spain
Argentina
Bangladesh
Europe
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Qatar
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Angola
Cyprus
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Yusuf Hamied invest in?

Yusuf Hamied invests primarily in Medical and Medical Device startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Yusuf Hamied?

Public channels for Yusuf Hamied include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Yusuf Hamied last invest?

The most recent investment recorded for Yusuf Hamied closed in Nov 2023. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Yusuf Hamied Yusuf Hamied Find email